Anika Therapeutics (ANIK) Shares Fall on FDA Timing Uncertainty

Anika Therapeutics, Inc. (Nasdaq: ANIK) shares are showing selling after-hours today following an announcement by the company that they still have not received timing for an FDA Advisory Panel meeting for MONOVISC. Additionally, the company said that the FDA did not approve their Bedford Facility, and will not until the equipment is permanently installed in Bedford. Finally, Anika said that they don't have timing set for three 510(k) premarket notifications filed for Anika Therapeutics S.r.l. products in October 2010. They were anticipating clearance for one at the end of 2010, and two before the end of Q111.

Shares are down 10.7% post-market.

Click here for full color from the release.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Eupraxia reports swallowing symptom data from EoE drug trial
• Sagimet gets FDA clearance for phase 3 acne trial of denifanstat
• Zipalertinib combo meets Phase 3 trial goal in lung cancer study